Pharmacy 777’s Post

🎉 Proudly Sharing My STAD Event 2024 Journey! 🎉 I'm thrilled✨to have completed Phase 1 of the STAD Event 2024, organized by PharmaSchemes! 📚 This incredible program provided 8 insightful sessions, covering crucial areas in the pharmaceutical industry. Here's a glimpse of what I learned: - Negotiation Skills: Mastering the art of effective communication and building strong professional relationships. 🤝 - Time Management & Prioritization: Learning to prioritize tasks and make the most of my time. ⏰ - Strategic Personal Branding: Building a strong professional presence that sets me apart. 🌟 - Sales Career in Pharma: Exploring the impact of pharma sales on healthcare. 🏥 - Enteral & Parenteral Nutrition: Gaining a deeper understanding of nutrition methods. - OTC Medications: Expanding my knowledge of over-the-counter medications and their role in patient care. 💊 This experience has been invaluable, enriching my knowledge and skills, and preparing me for exciting opportunities in pharmaceutical manufacturing. 💪 I'm eager to apply these learnings in my professional journey! #PharmaceuticalIndustry #LearningJourney #ProfessionalDevelopment #PharmaSkills #ClinicalPharmacy #OTCMedications #PharmaSchemes #STADEvent2024 #PersonalBranding #Nutrition

18 Pharma companies in the Club of 300 An analysis of the Top 300 brands (value wise) throws up some very interesting data. SUN PHARMA rules the list with whooping 29 brands, of which over 50% are growing in double digits! Abbott is near second, with 27 brands in Top 300 and 14 of these with double digit growths. Cipla, MANKIND PHARMA LTD & Alkem Laboratories Ltd. follow through with 21, 20 and 17 brands and 11, 9 and 6 brands with double digit growths, respectively. Connect Saurabh Chaturvedi to grow together!!

Securing the VOWST commercialization right: Nestlé Health Science VOWST is the first and only U.S. Food and Drug Administration (FDA)-approved orally administered microbiota-based therapeutic to prevent recurrence of Clostridioides difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI (rCDI). Seres Therapeutics, Inc. (Nasdaq: MCRB), announced today that it has agreed to a non-binding memorandum of understanding with Nestlé Health Science in which Nestlé Health Science will acquire certain tangible and intangible assets associated with VOWST (fecal microbiota spores, live-brpk) capsules. This transaction, when completed, supersedes any prior agreements between Nestlé and Seres concerning VOWST. Nestlé Health Science has been the lead commercialization party for the product since its launch in June 2023 in the United States. This transaction will allow Nestlé Health Science full control over the further development, commercialization, and manufacturing of VOWST in the US and worldwide. To read our last M&A publication: FMCG CEOs: M&A Q1 2024 In Review - A New Bottom & Four Reinforcing Trends 𝗟𝗶𝗻𝗸 𝘁𝗼 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗽𝘂𝗯𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻: https://lnkd.in/efD5RNWX 𝗧𝗼 𝗴𝗲𝘁 𝗮𝗹𝗹 𝗼𝘂𝗿 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝘀, 𝗳𝗼𝗹𝗹𝗼𝘄 𝘂𝘀 & 𝘀𝘂𝗯𝘀𝗰𝗿𝗶𝗯𝗲 𝘁𝗼 𝗼𝘂𝗿 𝗙𝗠𝗖𝗚 𝗖𝗘𝗢 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀 𝗻𝗲𝘄𝘀𝗹𝗲𝘁𝘁𝗲𝗿: https://lnkd.in/ea4gy65y #fmcg #cpg #consumerhealth Haleon Kenvue Sanofi Bayer | Consumer Health Reckitt Procter & Gamble https://lnkd.in/d83Czr9X

Global #Compounding #Pharmacies Market size was valued at USD 11.33 Billion in 2021 and is projected to reach USD 15.84 Billion by 2028, growing at a CAGR of 5.85% from 2021 to 2028 according to a new report by IMIR Market Research Pvt. Ltd. Compounding pharmacies are specialized facilities that prepare customized medications to cater to individual patient needs. Unlike standard pharmacies that dispense mass-produced drugs, compounding pharmacies formulate medications from scratch, allowing for personalized dosages, ingredients, and delivery methods. Request sample Report 👉 https://lnkd.in/d6YXm_rk Report Focused on Top Companies: ADVance Care Pharmacy AmerisourceBergen Arizona Museum of Natural History Arkopharma ATHENEX PHARMA SOLUTIONS, LLC Avella Specialty Pharmacy BKK B. Braun Melsungen AG Belle Sante® Diagnostic & Therapeutic Institute Bio-Botanica Inc Blackmores Group Clinigen DOUGHERTY'S PHARMACY MCALESTER, LLC. Elixir Compounding Pharmacy Fagron Fresenius Kabi Schweiz Guangzhou Pharmaceuticals Corporation Hainan Haiyao Co., Ltd Herbal Factory Africa Hoye's Pharmacy Institutional Pharmacies Of Louisiana ITC Compounding Pharmacy Kunming Pharmaceutical Co., Ltd. Madaus GmbH McGuff Companies. NATURE HERBS Nature's Answer Nephron Pharmaceuticals Olympia Pharmaceuticals Panacea Biotec Panaceutics Nutrition, Inc. PENCOL COMPOUNDING PHARMACY Perrigo Company plc PharMEDium Services

📰 Roquette marks another successful step in its journey to reinforce its position in the health and nutrition markets with the successful completion of its inaugural EUR 1.2 Billion Bond Offering. Pierre Courduroux, CEO of Roquette declared: “We are extremely proud of the success of this inaugural bond issuance, which marks a significant milestone in our long history of value creation for all our stakeholders. The strong demand from investors reflects their confidence in our strategy and our ability to continue innovating and expanding into high-growth markets. Once we complete the acquisition of IFF Pharma Solutions, we will not only expand our capabilities in the pharmaceutical excipients sector but also transform Roquette into a company with a more balanced Health and Nutrition offering and an expanded global presence." The net proceeds from the bond offering will mainly be used to refinance the announced acquisition of IFF Pharma Solutions, expected to close in the first half of 2025. Link to the press release in the first comment 👇

Get to know your Field Sauce Health Team. Over the coming weeks we will be sharing more information about members of the Field Sauce Health team and the wealth of experience that they bring to your studies. Today the spotlight is on Ewan. Ewan has 20+ years of pharmaceutical Market Research experience and a vast skillset which can be read in his biography below. #FieldSauceHealth #Insights #HealthcareMarketResearch #BHBIA

We're proud to contribute STADA's growth in the first half of 2024 as STADA Emerging Markets. Group revenues with above-market growth of 9% take half-year turnover over €2 billion, resulting in double-digit profit increase. Locally, STADA Pharmaceuticals has contributed strongly with solid turn-over and profit growth. Our success in Australia and New Zealand wouldn’t have been possible without the dedication of our incredible team and the trust of our clients and partners.    • Specialty was STADA’s fastest-growing and highest-margin segment in the first half of 2024, driven by an expanding biosimilars offering and roll-out of differentiated neurology and nephrology brands     • STADA CEO Peter Goldschmidt said: ‟STADA’s ongoing growth journey bears testimony to the strength and resilience of our three-pillar strategy – Consumer Healthcare, Specialty and Generics. Our continued growth ahead of market averages is compelling proof that our strong culture drives our performance.”   Stay tuned for more updates and opportunities as we continue to grow and make an impact!   Read the full story here in our media release: https://lnkd.in/dN-VP86Q #Stadanews #OneStada #Stada

What has been the outcome of the audits conducted on Alex Brun's company in the past few years?🤔 The company has consistently received grade A or higher rankings in the audits conducted by NSF and FDA. Alex Brun, VP and head of sales at Willings Nutraceutical, shares insights on how their company developed SOPs aligned with NSF and FDA guidelines over the past two decades. With a consistent track record of grade A audits, Alex delves into the strategies behind their success and why maintaining high standards is non-negotiable. Tune in for valuable lessons and inspiration. 🎧Listen Now: https://lnkd.in/gxCfJ34H   #NutraPreneur #NutraPayments #NutraceuticalMerchant #Innovation #HealthAndWellness #SustainableHerbs #Herbalism #EthicalBusiness #NutraceuticalBusiness #SecurePayments #PaymentSolutions #MerchantAccount #SecureTransactions 

#Acute_Bacterial_Skin and #Skin_Structure_Infections (#ABSSSI) Market is flourishing at a significant #growth_rate due to increasing ABSSSI incidence rates, antibiotic resistance, advancements in treatment options, and rising #healthcare expenditure and awareness initiatives. 🌐𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐭𝐨 𝐁𝐥𝐮𝐞𝐖𝐞𝐚𝐯𝐞 𝐅𝐨𝐫 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 "𝐀𝐜𝐮𝐭𝐞 𝐁𝐚𝐜𝐭𝐞𝐫𝐢𝐚𝐥 𝐒𝐤𝐢𝐧 𝐚𝐧𝐝 𝐒𝐤𝐢𝐧 𝐒𝐭𝐫𝐮𝐜𝐭𝐮𝐫𝐞 𝐈𝐧𝐟𝐞𝐜𝐭𝐢𝐨𝐧𝐬 (𝐀𝐁𝐒𝐒𝐒𝐈) 𝐌𝐚𝐫𝐤𝐞𝐭" ➖ https://lnkd.in/gFjadUEB ▶ 𝐌𝐚𝐣𝐨𝐫 𝐩𝐥𝐚𝐲𝐞𝐫𝐬: ✔Pfizer,  ✔Merck & Co.,  ✔AbbVie,  ✔Johnson & Johnson,  ✔Eli Lilly and Company,  ✔Novartis, ✔Sanofi, ✔AstraZeneca, ✔Teva Pharmaceuticals, ✔Mylan ✔Wohlfahrtsstiftung der F. Hoffmann-La Roche AG, GSK, 📢𝐌𝐚𝐫𝐤𝐞𝐭 – 𝐁𝐲 𝐃𝐢𝐬𝐭𝐫𝐢𝐛𝐮𝐭𝐢𝐨𝐧 𝐂𝐡𝐚𝐧𝐧𝐞𝐥: #ABSSSI_Market is divided into #Hospital #Pharmacies, #Retail_Pharmacies, and #Online_Pharmacies segments. The hospital pharmacies segment dominates the Global ABSSSI Market due to their ability to manage complex #infections effectively, provide timely access to necessary #medications, and offer advanced #healthcare_infrastructure, particularly in hospital settings where immediate and intensive care is required. #BlueWeave #Consulting #marketforecast #marketresearch #medicaldevices #pharmaindustry

Charles Joynson, WaveData MD, was in attendance at the Healthcare Distribution Association (HDA UK) Business Day, held in Edgbaston Stadium in Birmingham last week. Hosted by HDA Executive Director Martin Sawer, the agenda covered a number of topics including Community Pharmacy, working towards net zero, and the HDA strategy for the coming year. Most notable for Charles was the presentation by David Watson, The Association of the British Pharmaceutical Industry (ABPI) Commercial Policy Director on the Voluntary Scheme David Watson spoke about the total drugs bill for the UK. This he said made up about 10% of NHS spending in the UK, which in comparison with the rest of Europe (15%) and the USA (20%) was relatively low. This gives us some indicators behind the difficulty the NHS is having in paying for medicines. In the branded sphere we have large rebates which companies have to pay back to the Department of Health as part of the VPAG voluntary scheme, and in the generics sphere we have Category M which forces drug prices to very low levels. Some UK generics are reimbursed at prices that are so low that you couldn’t make and distribute a bar of chocolate for the same amount of money. Pharmaceuticals are complicated to make, distribute and quality check, and come with high risks – let’s face it, if you get it wrong people could die. Should the end product cost really be less than a bar of chocolate? At both ends of the spectrum, we can see that companies are having difficulty making money out of pharmaceuticals. Branded companies are threatening to leave the UK or to withdraw their branded products from sale in the UK. Generic companies are repeatedly finding themselves in loss making territory with individual products, meaning that they go through continual boom and bust cycles. The squeeze on pharmaceutical prices is also affecting patients. We have seen record numbers of products in short supply, with some patients unable to find their prescribed medication despite contacting many pharmacies in their local area or even further afield.